TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Detecting endometrial cancer
Key Statistics
- 9000+ — New UK EC cases/year
- 90% — EC presents with PMB
- ≥4–5 mm — BGCS TVS thickness cut-off
Don't-miss facts
-
PMB = bleeding >12 months after menopause; >90% of EC presents with PMB, but >90% of PMB is benign
-
NICE NG12: 2WW referral for PMB ≥55 years (consider if <55); refer HRT-associated unscheduled bleeding if >6 months, or new PMB persisting >6 weeks after stopping HRT
-
BGCS pathway: TVS first-line → endometrial biopsy ± hysteroscopy if endometrium thickened (cut-off ≥4–5 mm)
-
Pipelle biopsy failure 11%, inadequate sample 31% – 4.5% of "inadequate" samples were later EC, so do not falsely reassure
-
Hysteroscopy: sensitivity 86.4%, specificity 99.2%; Cochrane review shows no proven analgesic benefit from opioids/local anaesthetic at outpatient hysteroscopy – offer GA option and vaginoscopic technique
-
Every 5 kg/m² BMI rise → 50% ↑EC risk; Lynch syndrome → 25–60% lifetime risk (annual TVS/hysteroscopy/biopsy from age 35 per BGCS)
-
Tamoxifen: 3× ↑EC risk but also causes false-positive TVS appearances (stromal hypertrophy)
-
No UK EC screening programme exists; novel non-invasive detection tools (urine, blood, vaginal self-sampling) remain investigational, unvalidated
TVS thickness cut-offs (sens/spec)
≥4mm: 95.7% / 46.0% ≥5mm: 96.2% / 51.5% ≥10mm: 78.2% / 83.7% ≥15mm: 58.9% / 94.2%
Abbreviation Key
- EC — endometrial cancer
- NPV — negative predictive value
- PMB — postmenopausal bleeding
- 2WW — two-week wait
- TVS — transvaginal sonography/ultrasound scan
- MRI — magnetic resonance imaging
- NICE — National Institute for Health and Care Excellence
- CT — computed tomography
- BGCS — British Gynaecological Cancer Society
- NSAID — nonsteroidal anti-inflammatory drug
- SIGN — Scottish Intercollegiate Guidelines Network
- UKCTOCS — UK Collaborative Trial of Ovarian Cancer Screening
- RCOG — Royal College of Obstetricians and Gynaecologists
- HPV — human papillomavirus
- BMI — body mass index
- CA125 — cancer antigen 125
- PCOS — polycystic ovary syndrome
- HE4 — human epididymis protein 4
- HRT — hormone replacement therapy
- CTC — circulating tumour cell
- AEH — atypical endometrial hyperplasia
- ctDNA — circulating tumour DNA
- CI — confidence interval
- miRNA — microRNA
Source: Jones ER et al. Detecting endometrial cancer. The Obstetrician & Gynaecologist 2021;23:103–112. doi:10.1111/tog.12722
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).